BNP Paribas Financial Markets Buys 15,900 Shares of ProQR Therapeutics (NASDAQ:PRQR)

BNP Paribas Financial Markets increased its position in ProQR Therapeutics (NASDAQ:PRQR) by 27.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 74,701 shares of the biopharmaceutical company’s stock after purchasing an additional 15,900 shares during the period. BNP Paribas Financial Markets’ holdings in ProQR Therapeutics were worth $198,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. ArrowMark Colorado Holdings LLC bought a new stake in ProQR Therapeutics in the fourth quarter worth $3,131,000. Jane Street Group LLC bought a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $30,000. Northern Trust Corp lifted its stake in shares of ProQR Therapeutics by 2,550.1% in the 4th quarter. Northern Trust Corp now owns 417,398 shares of the biopharmaceutical company’s stock valued at $1,106,000 after purchasing an additional 401,648 shares during the last quarter. Boothbay Fund Management LLC boosted its holdings in shares of ProQR Therapeutics by 143.9% in the 4th quarter. Boothbay Fund Management LLC now owns 260,276 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 153,573 shares during the period. Finally, Two Sigma Securities LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at approximately $40,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Price Performance

Shares of PRQR stock opened at $1.74 on Friday. The company has a market cap of $183.07 million, a P/E ratio of -5.44 and a beta of 0.35. The stock’s 50-day moving average is $1.47 and its 200 day moving average is $2.22. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $4.90 million. On average, analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on PRQR shares. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Oppenheimer dropped their price target on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. Chardan Capital reissued a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research report on Friday, March 14th. Evercore ISI assumed coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They set an “outperform” rating and a $5.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They set an “overweight” rating and a $8.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).